This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Astellas Pharma, Inc.
Drug Names(s): Cytomegalovirus (CMV) vaccine, TransVax, VCL-CB01
Description: TransVax is a therapeutic, poloxamer-formulated DNA vaccine encoding the phosphoprotein 65 (pp65) antigen, designed to induce primarily a cellular immune response, and glycoprotein B (gB) antigen, designed to induce primarily an antibody response.
Vical and Astellas
In July 2011, Vical and Astellas Pharma announced that they have signed exclusive license agreements for the United States and for all territories in the rest of world outside the United States to develop and commercialize TransVax.
Under the agreements, Astellas will be responsible for further development and commercialization, including all costs. Vical has an option to co-promote TransVax in the United States. Vical will provide assistance to Astellas with TransVax-related manufacturing, regulatory and certain development activities, for which Astellas will reimburse all of Vical's future costs, including personnel and external expenses. Vical will receive near-term payments of $35 million, including $25 million upon the effective date and $10 million upon finalization of the Phase III trial design. Vical potentially will receive up to $130 million in total upfront and milestone payments through commercial launch and double-digit royalties on...See full deal structure in Biomedtracker
Partners: Vical, Inc.
Additional information available to subscribers only: